See more : LIDDS AB (publ) (LIDDS.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Next Science Limited (NXS.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Next Science Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Companhia Brasileira de Distribuição (PCAR3.SA) Income Statement Analysis – Financial Results
- Giant Manufacturing Co., Ltd. (9921.TW) Income Statement Analysis – Financial Results
- NexGen Energy Ltd. (0V9D.L) Income Statement Analysis – Financial Results
- Hostmore plc (MORE.L) Income Statement Analysis – Financial Results
- Thangamayil Jewellery Limited (THANGAMAYL.NS) Income Statement Analysis – Financial Results
Next Science Limited (NXS.AX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.nextscience.com
About Next Science Limited
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.18M | 16.90M | 8.64M | 3.83M | 4.11M | 2.63M | 0.00 | 85.58K |
| Cost of Revenue | 5.94M | 4.99M | 2.70M | 1.37M | 9.13M | 10.37M | 2.19K | 1.30M |
| Gross Profit | 16.23M | 11.90M | 5.94M | 2.47M | -5.02M | -7.74M | -2.19K | -1.22M |
| Gross Profit Ratio | 73.20% | 70.46% | 68.73% | 64.38% | -122.17% | -294.40% | 0.00% | -1,421.23% |
| Research & Development | 6.49M | 7.93M | 4.33M | 6.63M | 1.75M | 1.17M | 0.00 | 499.54K |
| General & Administrative | 5.61M | 5.39M | 2.98M | 2.41M | 5.94M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 20.17M | 10.31M | 5.36M | 4.33M | 457.38K | 0.00 | 0.00 | 0.00 |
| SG&A | 25.78M | 22.29M | 10.89M | 9.79M | 5.91M | 4.17M | 35.65K | 1.41M |
| Other Expenses | -16.03M | 71.97K | 192.40K | 417.02K | 51.83K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.23M | 30.22M | 15.22M | 16.43M | 7.66M | 5.34M | 35.65K | 1.91M |
| Cost & Expenses | 22.18M | 35.21M | 17.92M | 17.79M | 16.79M | 15.71M | 37.84K | 3.21M |
| Interest Income | 467.72K | 18.35K | 15.95K | 119.47K | 243.29K | 15.78K | 26.13 | 0.00 |
| Interest Expense | 735.92K | 41.26K | 15.91K | 23.59K | 2.16M | 73.73K | 10.97K | 8.78K |
| Depreciation & Amortization | 1.11M | 1.29M | 763.16K | 781.56K | 572.05K | 230.59K | 2.19K | 80.23K |
| EBITDA | -14.42M | -17.02M | -8.51M | -13.18M | -12.11M | -12.85M | -35.65K | -2.36M |
| EBITDA Ratio | -65.02% | -100.73% | -98.54% | -343.79% | -294.74% | -488.81% | 0.00% | -3,555.68% |
| Operating Income | -23.41M | -18.31M | -9.28M | -13.96M | -12.69M | -13.08M | -37.84K | -3.12M |
| Operating Income Ratio | -105.54% | -108.39% | -107.38% | -364.18% | -308.66% | -497.58% | 0.00% | -3,649.43% |
| Total Other Income/Expenses | 7.14M | -4.70M | -1.49M | -1.15M | -1.84M | 116.72K | -10.94K | 678.82K |
| Income Before Tax | -16.27M | -18.30M | -9.03M | -13.27M | -14.52M | -12.97M | -48.79K | -2.44M |
| Income Before Tax Ratio | -73.36% | -108.29% | -104.49% | -346.18% | -353.42% | -493.14% | 0.00% | -2,856.21% |
| Income Tax Expense | 0.00 | 4.00 | -2.17 | -3.83 | -1.41 | -1.41 | 1.58 | 1.44 |
| Net Income | -24.51M | -18.30M | -9.03M | -13.27M | -14.52M | -12.97M | -48.79K | -2.44M |
| Net Income Ratio | -110.52% | -108.29% | -104.49% | -346.18% | -353.42% | -493.14% | 0.00% | -2,856.21% |
| EPS | -0.10 | -0.09 | -0.05 | -0.07 | -0.08 | -0.07 | 0.00 | -0.01 |
| EPS Diluted | -0.10 | -0.09 | -0.05 | -0.07 | -0.08 | -0.07 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 234.09M | 210.47M | 196.88M | 187.19M | 165.98M | 179.16M | 179.16M | 179.16M |
| Weighted Avg Shares Out (Dil) | 234.09M | 210.47M | 196.88M | 187.19M | 165.98M | 179.16M | 179.16M | 179.16M |
Source: https://incomestatements.info
Category: Stock Reports